Эффекты антидепрессантов в терапевтической практике

1. Peano A., Calabrese F., Pechlivanidis K., et al. International Trends in Antidepressant Consumption: a 10-year Comparative Analysis (2010–2020). Psychiatr Q. 2025;96(2):241–55. https://dx.doi.org/10.1007/s11126-025-10122-0

2. Гомон Ю.М., Колбин А.С., Лаврова В.А. и др. Фармакоэпидемиология антидепрессантов в Российской Федерации. Реальная клиническая практика: данные и доказательства. 2025;5(1):49–58.

3. Kaplan A.G. Do Antidepressants Worsen COPD Outcomes in Depressed Patients with COPD? Pulm Ther. 2024;10(4):411–26. https://dx.doi.org/10.1007/s41030-024-00277-9

4. Siraj R.A., Bolton C.E., McKeever T.M. Association between antidepressants with pneumonia and exacerbation in patients with COPD: a self-controlled case series (SCCS). Thorax. 2023;79(1):50–7. https://dx.doi.org/10.1136/thorax-2022-219736

5. Jelić I., Mihajlović G., Mihajlović F., et al. COPD and Depression Analysis in Regard to Obstructive Pulmonary Levels. Healthcare (Basel). 2023;11(8):1175. https://dx.doi.org/10.3390/healthcare11081175

6. Meikle C.K.S., Creeden J.F., McCullumsmith C., et al. SSRIs: Applications in inflammatory lung disease and implications for COVID-19. Neuropsychopharmacol Rep. 2021;41(3):325–35. https://dx.doi.org/10.1002/npr2.12194

7. Guignabert C., Raffestin B., Benferhat R., et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005;111(21):2812–9. https://dx.doi.org/10.1161/CIRCULATIONAHA.104.524926

8. Li X.Q., Wang H.M., Yang C.G., et al. Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats. Acta Pharmacol Sin. 2011;32(2):217–22. https://dx.doi.org/10.1038/aps.2010.187

9. Kawut S.M., Horn E.M., Berekashvili K.K., et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther. 2006;19(5):370–4. https://dx.doi.org/10.1016/j.pupt.2006.01.001

10. Shah S.J., Gomberg-Maitland M., Thenappan T., et al. Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest. 2009;136(3):694–700. https://dx.doi.org/10.1378/chest.08-2823

11. Vozoris N.T., Wang X., Austin P.C., et al. Serotonergic antidepressant use and morbidity and mortality among older adults with COPD. Eur Respir J. 2018;52(1):1800475. https://dx.doi.org/10.1183/13993003.00475-2018

12. Brown E.S., Sayed N., Van Enkevort E., et al. Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder. J Allergy Clin Immunol Pract. 2018;6(5):1604–12. https://dx.doi.org/10.1016/j.jaip.2018.01.010

13. Hempel P., Klein V., Michely A., et al. Amitriptyline inhibits bronchoconstriction and directly promotes dilatation of the airways. Respir Res 2023;24:262. https://dx.doi.org/10.1186/s12931-023-02580-6

14. Jeyakumar A., Brickman T.M., Haben M. Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy. Laryngoscope. 2006;116(12):2108–12. https://dx.doi.org/10.1097/01.mlg.0000244377.60334.e3

15. Calvi A., Fischetti I., Verzicco I., et al. Antidepressant Drugs Effects on Blood Pressure. Front Cardiovasc Med. 2021;8:704281. https://dx.doi.org/10.3389/fcvm.2021.704281

16. Beyazyüz M., Albayrak Y., Eğilmez O.B., et al. Relationship between SSRIs and Metabolic Syndrome Abnormalities in Patients with Generalized Anxiety Disorder: A Prospective Study. Psychiatry Investig. 2013;10(2):148–54. https://dx.doi.org/10.4306/pi.2013.10.2.148

17. Fagiolini A., Comandini A., Catena Dell’Osso M., et al. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033–49. https://dx.doi.org/10.1007/s40263-012-0010-5

18. Proudman R.G.W., Pupo A.S., Baker J.G. The affinity and selectivity of α-adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D-adrenoceptors. Pharmacol Res Perspect. 2020;8(4):e00602. https://dx.doi.org/10.1002/prp2.602

19. Данилов Д.С., Бровко М.Ю. Эволюция представлений о риске развития тираминового синдрома при терапии необратимыми неселективными ингибиторами моноаминоксидазы (к 70-летию начала использования этой группы антидепрессантов). Неврология, нейропсихиатрия, психосоматика. 2022;14(5):4–12.

20. Vieweg W.V., Wood M.A. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004;45(5):371–7. https://dx.doi.org/10.1176/appi.psy.45.5.371

21. Licht C., Penninx B., de Geus E. Effects of Antidepressants, but not Psychopathology, on Cardiac Sympathetic Control: A Longitudinal Study. Neuropsychopharmacol. 2012;37:2487–95. https://dx.doi.org/10.1038/npp.2012.107

22. Glassman A.H., O’Connor C.M., Califf R.M., et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701–9. https://dx.doi.org/10.1001/jama.288.6.701

23. Köhler-Forsberg O., Stiglbauer V., Brasanac J., et al. Efficacy and Safety of Antidepressants in Patients With Comorbid Depression and Medical Diseases: An Umbrella Systematic Review and Meta-Analysis. JAMA. Psychiatry. 2023;80(12):1196–207. https://dx.doi.org/10.1001/jamapsychiatry.2023.2983

24. O’Connor C.M., Jiang W., Kuchibhatla M., et al. SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56(9):692-9. https://dx.doi.org/10.1016/j.jacc.2010.03.068

25. Angermann C.E., Gelbrich G., Störk S., et al. MOOD-HF Study Investigators and Committee Members. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA. 2016;315(24):2683–93. https://dx.doi.org/10.1001/jama.2016.7635.

26. Dennis M., Forbes J., Graham C., et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technol Assess. 2020;24(22):1–94. https://dx.doi.org/10.3310/hta24220

27. Grech J., Chan M.V., Ochin C., et al. Serotonin-Affecting Antidepressant Use in Relation to Platelet Reactivity. Clin Pharmacol Ther. 2022;111(4):909–18. https://dx.doi.org/10.1002/cpt.2517

28. Ford A.C., Lacy B.E., Harris L.A., et al. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019;114(1):21–39. https://dx.doi.org/10.1038/s41395-018-0222-5

29. Jeong B., Sung T.S., Jeon D., et al. Inhibition of TRPC4 channel activity in colonic myocytes by tricyclic antidepressants disrupts colonic motility causing constipation. J Cell Mol Med. 2022;26(19):4911–23. https://dx.doi.org/10.1111/jcmm.17348

30. Teoh C.X.W., Thng M., Lau S., et al. Dry mouth effects from drugs used for depression, anxiety, schizophrenia and bipolar mood disorder in adults: systematic review. BJPsych Open. 2023;9(2):e53. https://dx.doi.org/10.1192/bjo.2023.15

31. Miller E.W., Shoup D.S., Recktenwald M.W., et al. Nefarious nausea: A systematic review and meta-analysis of the risks of nausea in the treatment of major depressive, obsessive-compulsive, and anxiety disorders with selective serotonin re-uptake inhibitors (SSRIs). J Affect Disord Rep. 2020;1:100016. ISSN 2666-9153. https://dx.doi.org/10.1016/j.jadr.2020.100016

32. Moayyedi P., Anglin R. Antidepressants for Functional Dyspepsia: New Indications for Old Therapies? Clin Gastroenterol Hepatol. 2016;14(3):393–4. https://dx.doi.org/10.1016/j.cgh.2015.12.006

33. Weston F., Carter B., Powell N., et al. Antidepressant treatment in inflammatory bowel disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2024;36(7):850–60. https://dx.doi.org/10.1097/MEG.0000000000002768

34. Goodhand J.R., Greig F.I., Koodun Y., et al. Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. Inflamm Bowel Dis. 2012;18(7):1232–9. https://dx.doi.org/10.1002/ibd.21846

35. Blackwell J., Alexakis C., Saxena S., et al. Association between antidepressant medication use and steroid dependency in patients with ulcerative colitis: a population-based study. BMJ Open Gastroenterol. 2021;8(1):e000588. https://dx.doi.org/10.1136/bmjgast-2020-000588

36. Barry K. Chronic Pancreatitis: Diagnosis and Treatment. Am Fam Physician. 2018;97(6):385–93.

37. Foster H.E. Jr., Hanno P.M., Nickel J.C., et al. Interstitial Cystitis Collaborative Research Network. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183(5):1853–8. https://dx.doi.org/10.1016/j.juro.2009.12.106

38. Li J., Yang L., Pu C., et al. The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis. Int Urol Nephrol. 2013;45(3):679–86. https://dx.doi.org/10.1007/s11255-013-0410-6

39. Maund E., Guski L.S., Gøtzsche P.C. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. CMAJ. 2017;189(5):E194–203. https://dx.doi.org/10.1503/cmaj.151104

40. Palmer S.C., Natale P., Ruospo M., et al. Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis. Cochrane Database Syst Rev. 2016 May 23;2016(5):CD004541. https://dx.doi.org/10.1002/14651858.CD004541.pub3

41. Jeon Y.H., Lim J.H., Jeon Y., et al. The impact of severe depression on the survival of older patients with end-stage kidney disease. Kidney Res Clin Pract. 2024;43(6):818–28. https://dx.doi.org/10.23876/j.krcp.22.268

42. Sarwar H., Zeshan M., Hussain N., et al. Navigating the intersection of mental health and kidney health: a systematic review of antidepressant safety in renal impairment. Discov Ment Health. 2025;5(1):36. https://dx.doi.org/10.1007/s44192-025-00163-z

43. Nagler E.V., Webster A.C., Vanholder R., et al. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012;27(10):3736–45. https://dx.doi.org/10.1093/ndt/gfs295

44. Cayley W.E. Jr. Antidepressants for the treatment of neuropathic pain. Am Fam Physician. 2006;73(11):1933–4.

45. Jang H.N., Oh T..J. Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy. Diabetes Metab J. 2023;47(6):743–56. https://dx.doi.org/10.4093/dmj.2023.0018

46. Moore R.A., Derry S., Aldington D., et al. Amitriptyline for fibromyalgia in adults. Cochrane Database Syst Rev. 2019;5(7):CD011824. https://dx.doi.org/10.1002/14651858.CD011824

47. Winslow B.T., Vandal C., Dang L. Fibromyalgia: Diagnosis and Management. Am Fam Physician. 2023;107(2):137–44.

48. Gupta H., Girma B., Jenkins J.S., et al. Milnacipran for the Treatment of Fibromyalgia. Health Psychol Res. 2021;9(1):25532. https://dx.doi.org/10.52965/001c.25532

49. Migliorini F., Maffulli N., Eschweiler J., et al. Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis. J Orthop Surg Res. 2023;18(1):504. https://dx.doi.org/10.1186/s13018-023-03995-z

50. Xu X.M., Liu Y., Dong M.X., et al. Tricyclic antidepressants for preventing migraine in adults. Medicine (Baltimore). 2017;96(22):e6989. https://dx.doi.org/10.1097/MD.0000000000006989

51. Pibernik-Okanović M., Ajduković D., Lovrenčić M.V., et al. Does treatment of subsyndromal depression improve depression and diabetes related outcomes: protocol for a randomised controlled comparison of psycho-education, physical exercise and treatment as usual. Trials. 2011;12:17. https://dx.doi.org/10.1186/1745-6215-12-17

52. Baumeister H., Hutter N., Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression. Cochrane Database Syst Rev. 2012;12(12):CD008381. https://dx.doi.org/10.1002/14651858.CD008381.pub2

53. Srisurapanont M., Suttajit S., Kosachunhanun N., et al. Antidepressants for depressed patients with type 2 diabetes mellitus: A systematic review and network meta-analysis of short-term randomized controlled trials. Neurosci Biobehav Rev. 2022;139:104731. https://dx.doi.org/10.1016/j.neubiorev.2022.104731

54. Wharton S., Raiber L., Serodio K.J., et al. Medications that cause weight gain and alternatives in Canada: a narrative review. Diab Metab Syndr Obes. 2018;11:427-438. https://dx.doi.org/10.2147/DMSO.S171365

55. Hilas O., Avena-Woods C. Potential role of mirtazapine in underweight older adults. Consult Pharm. 2014;29(2):124–30. https://dx.doi.org/10.4140/TCP.n.2014.124

56. Handley A.P., Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J Am Assoc Nurse Pract. 2015;27(1):54–61. https://dx.doi.org/10.1002/2327-6924.12137

57. Eker S.S., Akkaya C., Sarandol A., at al. Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(4):955–61. https://dx.doi.org/10.1016/j.pnpbp.2007.12.029

58. Выборных Д.Э., Иванов С.В., Гемджян Э.Г. и др. Психофармакотерапия психических расстройств у гематологических больных: проблемы безопасности. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2023;123(4–2):90–8.

59. Liu C., Zhou R., Peng X., et al. Relationship between depressive symptoms and anemia among the middle-aged and elderly: a cohort study over 4-year period. BMC Psychiatry. 2023;23(1):572. https://dx.doi.org/10.1186/s12888-023-05047-6

60. Vulser H., Lemogne C., Boutouyrie P., et al. Depression, antidepressants and low hemoglobin level in the Paris Prospective Study III: A cross-sectional analysis. Prev Med. 2020;135:106050. https://dx.doi.org/10.1016/j.ypmed.2020.106050

61. Cao Y., Li X., Gao J., et al. Revealing the Causal Relationship Between Differential White Blood Cell Counts and Depression: A Bidirectional Two-Sample Mendelian Randomization Study. Depress Anxiety. 2025;2025:3131579. https://dx.doi.org/10.1155/da/3131579

62. Szałach Ł.P., Lisowska K.A., Cubała W.J. The Influence of Antidepressants on the Immune System. Arch Immunol Ther Exp (Warsz). 2019;67(3):143–51. https://dx.doi.org/10.1007/s00005-019-00543-8

63. Sealock J.M., Chen G., Davis L.K. Anti-Inflammatory Action of Antidepressants: Investigating the Longitudinal Effect of Antidepressants on White Blood Cell Count. Complex Psychiatry. 2023;9(1–4):1–10. https://dx.doi.org/10.1159/000528605

64. Butler D.C., Berger T., Elmariah S., et al. Chronic Pruritus: A Review. JAMA. 2024;331(24):2114–24. https://dx.doi.org/10.1001/jama.2024.4899

65. Goldsobel A.B., Rohr A.S., Siegel S.C., et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1986;78(5 Pt. 1):867–73. https://dx.doi.org/10.1016/0091-6749(86)90232-0

66. Groene D., Martus P., Heyer G. Doxepin affects acetylcholine induced cutaneous reactions in atopic eczema. Exp Dermatol. 2001;10(2):110–7. https://dx.doi.org/10.1034/j.1600-0625.2001.010002110.x

67. Leaney A.A., Lyttle J.R., Segan J., et al. Antidepressants for hip and knee osteoarthritis. Cochrane Database Syst Rev. 2022;10(10):CD012157. https://dx.doi.org/10.1002/14651858.CD012157.pub2